Alseres Pharmaceuticals Inc., a Hopkinton biotechnology company, has enrolled 48 subjects at nine sites in the U.S. and Canada for the Phase I/IIa clinical trial of its acute spinal cord injury treatment.
Alseres’ Cethrin protein treatment promotes spinal cord nerve regeneration, and could potentially be administered to as many as 11,000 new spinal cord injury cases annually nationwide, the company said.
Pending results of the Phase I/IIa trial, the company also said it plans to begin a Phase IIb trial in acute spinal cord injury in the U.S., Canada and Europe before the end of this year.
